Evaluate the Efficacy and Safety of Rasburicase (Fasturtec ) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
-
- STATUS
- Recruiting
-
- participants needed
- 50
-
- sponsor
- Sanofi
Updated on 20 May 2022
lymphoma
acute leukemia
hodgkin's disease
leukemia
rasburicase
pediatric
non-hodgkin lymphoma
Summary
Primary Objective:
To evaluate safety of rasburicase in pediatric patients with NHL and AL
Secondary Objective:
To assess efficacy of rasburicase for prevention and treatment of hyperuricemia
Description
Study duration per participants is approximatively 14 days including a 5-day treatment period.
Details
| Condition | Lymphoma, non-hodgkin's lymphoma, Lymphoproliferative Disorder, lymphoproliferative disorders, Lymphoma, lymphoproliferative disorders, non-hodgkin's lymphoma |
|---|---|
| Age | 2years - 18years |
| Treatment | RASBURICASE SR29142 |
| Clinical Study Identifier | NCT04349306 |
| Sponsor | Sanofi |
| Last Modified on | 20 May 2022 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.